NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis

Neurocrine Biosciences, Inc. (NBIX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

NBIX

$155.64

−$2.71 (−1.71%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NBIX with… →

NBIX Key Statistics

As of Sep 4, 2026
Trading
Open
$158.24
Previous Close
$158.35
Day's Range
154.83–159.80
52-Week Range
122.14–186.12
Volume
933.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.38
Valuation
Market Cap
$15.82B
P/E Ratio
22.79
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.00
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.32
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.69
EPS (ttm)Profit attributable to each share over the last twelve months.
6.83
Financials (FY)
Revenue (FY)
$2.86B+21.45%
Net Income (FY)
$478.60M+40.23%
Profit marginThe share of revenue left as profit after all costs and taxes.
20.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
101.65M
1-Year Return
+10.85%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
1.23M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NBIX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+9.74%
2025+3.90%
2024+3.60%
2023+10.31%
2022+40.24%
2021−11.14%
2020−10.83%
2019+50.53%
2018−7.96%
2017+100.49%
2016 (partial year)−20.37%

As of September 4, 2026.

NBIX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.86B$478.60M16.7%
2024$2.36B$341.30M14.5%
2023$1.89B$249.70M13.2%
2022$1.49B$154.50M10.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.86B$2.81B$636.50M$478.60M16.7%
2024$2.36B$2.32B$583.00M$341.30M14.5%
2023$1.89B$1.85B$394.80M$249.70M13.2%
2022$1.49B$1.47B$249.00M$154.50M10.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NBIX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricNBIXDrug Manufacturers - Specialty & Generic medianvs median
P/E22.7919.2718% above
P/S ratio4.692.30104% above
Profit margin20.91%−3.14%24.0 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Neurocrine Biosciences, Inc. (NBIX) carries a market capitalisation of $15.82B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 2,500 employees.

Over the past 52 weeks the price has ranged from $122.14 to $186.12. The most recent close on file for NBIX is $155.64, dated September 4, 2026. That is −$2.71 (−1.71%) against the previous close. The latest close sits 27.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.86B. Against the prior fiscal year total of $2.36B, that is a change of +21.45%. Net income for the same year was $478.60M. That is +40.23% against the prior fiscal year. The reported profit margin is 20.91%. That is 24 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 6.83.

Across the 4 fiscal years on file, revenue moves from $1.49B in 2022 to $2.86B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 22.79. That is 18.3% above the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 13. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.32. Measured against sales, the shares trade at 4.69 times revenue. On price-to-sales that is 104.21% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is +10.85%. Measured over 10 years, that is +12.15% a year compounded. Beta against the wider market is reported at 0.38. Annualized volatility over the trailing 10 years is 39.12%.

Growth & Income

The record shows no dividend for NBIX.

So far in 2026 the price is +9.74%. The strongest complete calendar year on file is 2017 at +100.49%; the weakest is 2021 at −11.14%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Neurocrine Biosciences, Inc. (NBIX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Neurocrine Biosciences, Inc. NBIX $15.82B 22.8
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Neurocrine Biosciences, Inc. trades at a P/E of 22.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Visit website →